Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

Bibliography

• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480-91
   PubMed Web of Science ®Google Scholar
• Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303(7):G775-85
   PubMed Web of Science ®Google Scholar
• Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther 2014;39(10):1033-42
   PubMed Web of Science ®Google Scholar
• Sommer F, Backhed F. The gut microbiota – masters of host development and physiology. Nat Rev Microbiol 2013;11(4):227-38
   PubMed Web of Science ®Google Scholar
• Robles Alonso V, Guarner F. Linking the gut microbiota to human health. Br J Nutr 2013;109(Suppl 2):S21-6
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kanazawa M, Fukudo S, et al. Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil 2011;17(2):131-9
   PubMed Web of Science ®Google Scholar
• Ohman L, Tornblom H, Simren M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 2014;12(1):36-49
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95(12):3503-6
   PubMed Web of Science ®Google Scholar
• Simren M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut 2006;55(3):297-303
   PubMed Web of Science ®Google Scholar
• Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136(6):1979-88
   PubMed Web of Science ®Google Scholar
• Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007;26(4):535-44
   PubMed Web of Science ®Google Scholar
• Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome--a meta-analysis. Am J Gastroenterol 2006;101(8):1894-9; quiz 1942
   PubMed Web of Science ®Google Scholar
• Cremon C, Stanghellini V, Pallotti F, et al. Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology 2014;147(1):69-77
   PubMed Web of Science ®Google Scholar
• Yamini D, Pimentel M. Irritable bowel syndrome and small intestinal bacterial overgrowth. J Clin Gastroenterol 2010;44(10):672-5
   PubMed Web of Science ®Google Scholar
• Ohman L, Simren M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep 2013;15(5):323
   PubMedGoogle Scholar
• Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98(2):412-19
   PubMed Web of Science ®Google Scholar
• Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008;53(1):169-74
   PubMed Web of Science ®Google Scholar
• Ojetti V, Lauritano EC, Barbaro F, et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol 2009;5(6):675-82
   PubMed Web of Science ®Google Scholar
• Backhed F. Host responses to the human microbiome. Nutr Rev 2012;70(Suppl 1):S14-17
   PubMedGoogle Scholar
• Gasbarrini A, Lauritano EC, Garcovich M, et al. New insights into the pathophysiology of IBS: intestinal microflora, gas production and gut motility. Eur Rev Med Pharmacol Sci 2008;12(Suppl 1):111-17
   PubMedGoogle Scholar
• Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145(8):557-63
   PubMed Web of Science ®Google Scholar
• Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 2009;19(1):141-50; vii
   PubMedGoogle Scholar
• Marchi E, Montecchi L, Venturini AP, et al. 4-Deoxypyrido[1’,2’:1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J Med Chem 1985;28(7):960-3
   PubMed Web of Science ®Google Scholar
• Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49(3):467-84
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, Dupont HL. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents 2010;35(3):278-81
   PubMed Web of Science ®Google Scholar
• Brown EL, Xue Q, Jiang ZD, et al. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother 2010;54(1):388-96
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Migliorati M, Barbanti M, et al. Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol 2010;80(11):1700-7
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Renga B, Palladino G, et al. Inhibition of NF-kappaB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol 2011;668(1-2):317-24
   PubMed Web of Science ®Google Scholar
• Xu D, Gao J, Gillilland M, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 2014;146(2):484-96; e484
   PubMed Web of Science ®Google Scholar
• Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101(2):326-33
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364(1):22-32
   PubMed Web of Science ®Google Scholar
• Infantalino A DJ, Miller C, Rupisan I, et al. Small intestinal bacterial overgrowth (SIBO) in patients with irritable bowel syndrome (IBS); a retrospective review of symptoms following treatment (Abstract). Am J Gastroenterol 2009;104:S488-99
   Web of Science ®Google Scholar
• Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012;107(1):28-35. quiz 36
   PubMed Web of Science ®Google Scholar
• Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci 2011;56(7):2067-72
   PubMed Web of Science ®Google Scholar
• Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol 2011;4:43-8
   PubMedGoogle Scholar
• Weinstock LB. Long-term outcome of rifaximin therapy in non-constipation irritable bowel syndrome. Dig Dis Sci 2011;56(11):3389-90
   PubMed Web of Science ®Google Scholar
• Lembo A, Rao SS, Schoenfeld P, et al. Efficacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D): Results of the TARGET 3 study. In: American College of Gastroenterology Annual Meeting and Postgraduate Course; Philadelphia; 2014
   Google Scholar
• Cellai L, Cerrini S, Segre A, et al. A study of structure-activity relationships in 4-deoxypyrido[1’,2’-1,2]imidazo[5,4-c]rifamycin SV derivatives by electron spectroscopy for chemical analysis and 1H NMR. Mol Pharmacol 1985;27(1):103-8
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(Suppl 1):36-66
   PubMed Web of Science ®Google Scholar
• Darkoh C, Lichtenberger LM, Ajami N, et al. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother 2010;54(9):3618-24
   PubMed Web of Science ®Google Scholar
• Venturini AP. Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy 1983;29(1):1-3
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73(Suppl 1):13-27
   PubMed Web of Science ®Google Scholar
• Cellai L, Colosimo M, Marchi E, et al. Rifaximin (L/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats. Chemioterapia 1984;3(6):373-7
   PubMedGoogle Scholar
• Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14(2):51-6
   PubMedGoogle Scholar
• Cottreau J, Baker SF, DuPont HL, et al. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther 2000;8(7):747-60
   Google Scholar
• Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44(8):2205-6
   PubMed Web of Science ®Google Scholar
• XIFAXAN® (rifaximin) Tablets, 550 mg NDA 21-361 Briefing Document for Gastrointestinal Drugs Advisory Committee Meeting and XIFAXAN® Package Insert
   Google Scholar
• Cremonini F, Lembo A. Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother 2012;13(3):433-40
   PubMed Web of Science ®Google Scholar
• Taylor DN, McKenzie R, Durbin A, et al. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother 2008;52(3):1179-81
   PubMed Web of Science ®Google Scholar
• Rizzello F, Gionchetti P, Venturi A, et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 1998;54(1):91-3
   PubMed Web of Science ®Google Scholar
• Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005;3(2):201-11
   PubMedGoogle Scholar
• Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012;107(7):991-1000
   PubMed Web of Science ®Google Scholar
• Pae CU, Masand PS, Ajwani N, et al. Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. Int J Clin Pract 2007;61(10):1708-18
   PubMed Web of Science ®Google Scholar
• Masand PS, Kaplan DS, Gupta S, et al. Irritable bowel syndrome and dysthymia. Is there a relationship? Psychosomatics 1997;38(1):63-9
   PubMed Web of Science ®Google Scholar
• Koo HL, Sabounchi S, Huang DB, et al. Rifaximin therapy of irritable bowel syndrome. Clin Med Insights Gastroenterol 2012;5:31-41
   PubMedGoogle Scholar
• Salix Pharmaceuticals, Inc. In vitro assessment of induction potential of rifaximin and rifampicin in primary human hepatocytes. In. 2010
   Google Scholar
• Trapnell CB, Connolly M, Pentikis H, et al. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 2007;41(2):222-8
   PubMed Web of Science ®Google Scholar
• Pentikis HS, Connolly M, Trapnell CB, et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 2007;27(10):1361-9
   PubMed Web of Science ®Google Scholar
• Ma X, Shah YM, Guo GL, et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007;322(1):391-8
   PubMed Web of Science ®Google Scholar
• Hoffman JT, Hartig C, Sonbol E, et al. Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. Ann Pharmacother 2011;45(5):e25
   Google Scholar
• Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn’s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23(8):1117-25
   PubMed Web of Science ®Google Scholar
• Prantera C, Lochs H, Grimaldi M, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn’s disease. Gastroenterology 2012;142(3):473-81; e474
   PubMed Web of Science ®Google Scholar
• Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2014;39(10):1161-8
   PubMed Web of Science ®Google Scholar
• Salix Pharmaceuticals Inc. A phase 2, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of three different doses (275, 550, and 1100 mg) of rifaximin administered BID for either two or four weeks in the treatment of patients with diarrhea-associated irritable bowel syndrome (RFIB2001). In. 2008
   Google Scholar
• Gomes C, Ruiz L, Pons MJ, et al. Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates. Trans R Soc Trop Med Hyg 2013;107(9):545-9
   PubMed Web of Science ®Google Scholar
• Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014;12(8):1390-7; e1392
   PubMed Web of Science ®Google Scholar
• Maccaferri S, Vitali B, Klinder A, et al. Rifaximin modulates the colonic microbiota of patients with Crohn’s disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 2010;65(12):2556-65
   PubMed Web of Science ®Google Scholar
• American Gastroenterology A. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology 2002;123(6):2105-7
   PubMed Web of Science ®Google Scholar